In the current study carried out in the Dp16 mouse model of DS, in vivo administration of App‐ and Rab5‐specific ASOs reduced App and Rab5 gene expression, normalized RAB5 activity, and restored other endosomal Rab activities. This evidence concerns the gene RAB5A and Dravet syndrome.